Nuvectis Pharma, Inc.
NVCTHealthcare|Biotechnology|US
$20.91
+3.15 (+17.74%)
DCF Value
$1.18
Tangible Book / Share
$4.30
Cash / Share
$4.78
About
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Stock Price
+268.8%(1Y)
1M
+3.9%
3M
+10.3%
6M
+79.5%
YTD
+177.0%
1Y
+244.5%
3Y
+153.8%
5Y
+543.4%
Pipeline Summary
4 total trials4
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Active: 1Recruiting: 2Terminated: 1
Active Trials (3)
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686Advanced Solid Tumor
Phase 1Active
Enrollment: 140 participants
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
NCT07315113EGFR Mutation Positive Non-small Cell Lung Cancer
Phase 1Recruiting
Enrollment: 18 participants
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
NCT07784959ALK Positive
Phase 1Recruiting
Enrollment: 54 participants
Key Facts
Market Cap$682.6M
Employees13 (+0% YoY)
CEORon Bentsur
IPO DateFeb 4, 2022
Beta-0.24
52-Week Range$5.77 – $29.28
Avg Volume223,570
ExchangeNASDAQ
Websitenuvectis.com
Ownership
Float64.8%
Shares Outstanding32.6M
Recent Insider Trades
Carson Michael J.AWARD
Aug 3, 202630,000 shares
Mosseri Marlio CharlesBUY
Jun 30, 202650,000 shares @ $18.32
BENTSUR RONBUY
Jun 30, 202612,500 shares @ $20.00
Hoberman KennethAWARD
Jun 11, 202635,000 shares
Oliviero James F IIIAWARD
Jun 11, 202635,000 shares
Peers
Recent News
Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript
Nov 4, 2026 · seekingalpha.com
Nuvectis Pharma Q3 Earnings Call Highlights
Nov 4, 2026 · marketbeat.com
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
Nov 4, 2026 · globenewswire.com
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
Nov 2, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:25 AM